The effect of left atrial appendage closure on heart failure biomarkers: A PRAGUE‐17 trial subanalysis

Autor:	Vivek Y. Reddy, Petr Neuzil, Petr Widimsky, Pavel Hala, Prague Trial Investigators, Veronika Lekesova, Pavel Osmancik, Marek Hozman, Jiri Jarkovsky, Martina Novackova, Klára Benešová, Dalibor Herman
Rok vydání:	2021
Předmět:	medicine.medical_specialty Reservoir function Administration Oral 030204 cardiovascular system & hematology 03 medical and health sciences 0302 clinical medicine Atrial natriuretic peptide Left atrial Physiology (medical) Internal medicine Atrial Fibrillation medicine Humans Atrial Appendage Heart Failure business.industry Anticoagulants Serum concentration Brain natriuretic peptide medicine.disease 3. Good health Stroke 030220 oncology & carcinogenesis Baseline characteristics Heart failure Cardiology Cardiology and Cardiovascular Medicine business Biomarkers
Zdroj:	Journal of Cardiovascular Electrophysiology. 32:2645-2654
ISSN:	1540-8167 1045-3873
Popis:	Introduction The randomized PRAGUE-17 trial demonstrated non-inferiority of LAAC to NOAC for the prevention of major cardiovascular or cerebrovascular events. However, the LAA is an important source of natriuretic peptides and plays a role in left atrial reservoir function. Changes of HF biomarkers after LAAC compared to NOAC has not been studied. The aim of the study was to compare the changes in concentrations of heart failure (HF) biomarkers between left atrial appendage closure (LAAC) and non-vitamin K anticoagulants (NOAC) patients. Methods Of 402 patients randomized in the PRAGUE-17 trial, biomarkers were analyzed in 144 patients (73 in the NOAC and 71 in the LAAC group). Both groups had similar baseline characteristics. Serum concentration of NT-proBNP, NT-proANP, Galectin-3, and GDF-15 were measured at baseline (before the procedure in the LAAC group), at the 6-month (and at 24-month for NT-proBNP) follow-up timepoint. Results There were no significant differences in baseline, 6-month, and delta (δ = baseline - 6-month) concentrations of NT-proANP between the groups (NOAC: baseline 2.6 (0.5; 4.9), 6-month 3.1 (1.8; 4.8), p=0.068; LAAC: baseline 3.3 (1.1; 4.6), 6-month 2.6 (0.9; 5.3), p=0.51; p value for δ in concentrations between groups = 0.42). Similarly, there were no significant differences in baseline, 6-month, 24-monht and delta concentrations of NT-proBNP between the groups (NOAC: baseline 461.0 (113.5; 1342.0), 6-month 440.0 (120.5; 1291.5), 24-month 798 (274; 2236), p = 0.39; LAAC: baseline 421.0 (100.0; 1320.0), 6-month 601.0 (145.0; 1230.0), 24-month 855 (410; 1367), p=0.28; p value for δ in concentrations between groups = 0.73 at 6 months, and 0.58 at 24 months). Finally, no significant differences were present in baseline, 6-month, and δ concentrations of Galectin-3 and GDF-15 between the two groups. Conclusion LAAC did not significantly influence the levels of HF biomarkers 6 months after the procedure. This article is protected by copyright. All rights reserved.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a679c3c7eb68989530bac5af5c14275c https://doi.org/10.1111/jce.15206 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.